Rocket Pharmaceuticals (RCKT) officer sells 384 shares to cover RSU tax withholding

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. officer John Militello reported selling 384 shares of common stock at $3.014 per share on May 19, 2026. According to the footnotes, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.

After this transaction, Militello directly holds 89,780 shares of common stock. The filing characterizes the trade as an open-market sale but clarifies that its purpose was to cover taxes related to equity compensation rather than a discretionary portfolio adjustment.

Insider Trade Summary

Net Seller: 384 shares ($1,157)

Net Sell 1 txn

Insider Militello John

Role See Remarks

Sold 384 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock	384	$3.014	$1K

Holdings After Transaction: Common Stock — 89,780 shares (Direct, null)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Key Figures

Shares sold: 384 shares Sale price per share: $3.014 per share Shares held after transaction: 89,780 shares +1 more

4 metrics

Shares sold 384 shares Open-market sale on May 19, 2026

Sale price per share $3.014 per share Price for common stock sold on May 19, 2026

Shares held after transaction 89,780 shares Direct common stock holdings after May 19, 2026 sale

Net shares sold 384 shares Net-sell direction per transaction summary

Key Terms

Restricted Stock Units ("RSUs"), tax withholding obligations, open-market sale, Form 4

4 terms

Restricted Stock Units ("RSUs") financial

"Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligations financial

"The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Militello John

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NEW JERSEY 08512

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	05/19/2026		S(2)		384	D	$3.014	89,780(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Remarks:

Vice President of Finance, Treasurer, Principal Accounting Officer

	/s/ Martin Wilson, as attorney-in-fact for John Militello	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RCKT officer John Militello report?

John Militello reported selling 384 shares of ROCKET PHARMACEUTICALS common stock. The shares were sold at $3.014 each to cover tax withholding obligations tied to vesting Restricted Stock Units, rather than as a discretionary sale of his equity position.

Why did John Militello sell Rocket Pharmaceuticals (RCKT) shares?

The sale was made to pay tax withholding obligations from RSUs vesting. Footnotes state the 384 shares of common stock were sold specifically to cover taxes owed when Restricted Stock Units converted into shares, a common mechanism for equity compensation.

How many Rocket Pharmaceuticals (RCKT) shares does Militello hold after the transaction?

Following the reported sale, Militello directly holds 89,780 shares of common stock. This figure includes holdings associated with RSUs that convert to common stock on a one-for-one basis, as indicated in the footnotes to the Form 4 filing.

Was the RCKT insider trade an open-market sale or part of compensation?

The transaction is coded as an open-market sale but tied to compensation. Footnotes explain the 384 shares were sold specifically to satisfy tax withholding obligations from Restricted Stock Unit vesting, linking the trade directly to equity compensation rather than an independent investment decision.

What role do RSUs play in John Militello’s Rocket Pharmaceuticals (RCKT) holdings?

Militello’s holdings include Restricted Stock Units that each convert into one share of common stock. The Form 4 notes that RSUs contribute to his total share position and that the reported sale was triggered by tax obligations related to the vesting of those RSUs.